EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Xian International Medical Investment Co Ltd (000516) fair value: what the stock is really worth

As of Sep 22, 2026: fair value of Xian International Medical Investment Co Ltd ¥3.42, price ¥4.32, upside -20.8%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · CN · ISIN CNE000000016

XI Thin data Sep 24, 2026

Xian International Medical Investment Co Ltd

000516 · SHE

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value ¥3.42 · Overvalued (−21%)
!Quality 54/100
!Mixed Growth (revenue 5y +20.5 %/yr)
!Loss-making · -6.3% net margin (TTM)
✓Moderate debt · generates free cash flow
!Trails peers (4/13)
!Narrow moat 11/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 6 out of 100
Watch Xian International Medical Investment Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥21.13 ¥3.86 Fair Value ¥3.42 Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range ¥3.86 – ¥21.13 · fair‑value band ¥2.14 – ¥5.02 · the ¥4.32 price screens above the ¥3.42 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.

Follow Xian International Medical Investment Co in your weekly email

Every Wednesday you see whether Xian International Medical Investment Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Xi'an International Medical Investment Company Limited provides healthcare services. It operates hospitals and medical centers. It also engages in insurance broking, tourism, and pharmaceutical production business. Xi'an International Medical Investment Company Limited was formerly known as Xi'an Kaiyuan Investment Group Co., Ltd.

Show more

Xi'an International Medical Investment Company Limited provides healthcare services. It operates hospitals and medical centers. It also engages in insurance broking, tourism, and pharmaceutical production business. Xi'an International Medical Investment Company Limited was formerly known as Xi'an Kaiyuan Investment Group Co., Ltd. and changed its name to Xi'an International Medical Investment Company Limited in January 2015. The company was founded in 1986 and is based in Xi'an, China.

Stock analysis

Xian International Medical Investment Co Ltd (000516) currently trades at ¥4.32, while our model-based Fair Value estimate is ¥3.42, implying the stock looks roughly 26.3% overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of ¥3.39 per share, and 2 of the 11 models we run sit above the ¥4.32 price.

Bear case: the Asset-Based group reads lowest at ¥0.9900, and 9 of the 11 models stay below the price. Evidence for this calculation is low.

Scenario range: ¥2.14 (bear) to ¥5.02 (bull), the price of ¥4.32 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Xian International Medical Investment Co Ltd reported revenue of 4.1B CNY in FY2025 versus 2.9B CNY in FY2021, a compound +8.7%/yr. Reported net income was −313M CNY in FY2025.

Key figures

Market cap 9.7B CNY (≈ $1.4B) · P/S ratio 2.35 · EPS (TTM) ¥−0.1100 · Dividend yield 1.6% · Net margin −7.7% · Return on equity −11.5% · Return on assets (EBIT) −5.1% · Operating margin −4.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 30% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −21%, 000516 screens richer than that median.

Fair Value models

Bear ¥2.14 Fair Value ¥3.42 Bull ¥5.02
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF ¥4.37 ¥7.50 ¥12.13 78
Growth DCF ¥4.31 ¥7.12 ¥11.05 77
5Y EBITDA Exit ¥2.04 ¥3.25 ¥4.64 75
All 11 models by family
DCF Models
FCF DCF ¥4.37 ¥7.50 ¥12.13 78
Owner Earnings ¥0.2300 ¥0.8500 ¥1.76 70
5Y Revenue Exit ¥2.08 ¥3.34 ¥4.90 72
5Y EBITDA Exit ¥2.04 ¥3.25 ¥4.64 75
10Y Revenue Exit ¥2.88 ¥4.28 ¥6.15 67
10Y EBITDA Exit ¥2.90 ¥4.22 ¥5.96 68
Multiples
EV/EBITDA ¥0.7700 ¥1.29 ¥1.81 65
EV/Revenue ¥0.7400 ¥1.40 ¥2.05 52
Asset-Based
NCAV (Graham) ¥0.7400 ¥0.9900 ¥1.48 54
Growth DCF
Growth DCF ¥4.31 ¥7.12 ¥11.05 77
Rev-Margin DCF ¥2.08 ¥3.39 ¥5.05 72

Open the full fair value analysis →

Notify me when 000516 reaches fair value

Put 000516 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 54/100

Of which business quality 54 · Market factors (momentum, volatility) 41

Profitability 8
Margins and returns on capital today
Quality Growth 40
Are margins and returns improving?
Cashflow 91
Earnings quality: real cash, not paper profit
Fin. Strength 27
Balance sheet, leverage, solvency risk
Investment 92
Disciplined investing over empire-building
Low Volatility 75
Calm price path (market factor)
Momentum 33
Price trend over the last 3–12 months (market factor)
52W Momentum 17
Distance to the 52-week high (market factor)
Net Issuance 92
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 61/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−15.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.5%
Start year 2020 (pandemic). Over 10 years: +0.4% a year
Revenue growth 34 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−38.2% (2019) → −7.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+1.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +0.2% a year for the price.

000516 screens 26% overvalued. Compare with HCA Healthcare, Inc →

Compare Xian International Medical Investment Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 257 stocks

Beats the industry median on 4/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 54 · Below median
Fair Value upside −21% · Below median
Profitability
Return on assets −1% · Bottom 25%
Net margin (TTM) −6% · Bottom 25%
Operating margin (TTM) −4% · Bottom 25%
Growth and dividend
Revenue growth −3% · Bottom 25%
Dividend yield (TTM) 1.6% · Below median
Balance sheet
Debt / equity 0.65× · Highest 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 0.44× · Cheapest 25%
P/S (TTM) 0.36× · Cheapest 25%
P/FCF 1.4× · Cheaper than median
EV/EBITDA 7.6× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)6 · sector 33
FUTURE (revenue growth)0 · sector 29
PAST (return on equity)0 · sector 31
HEALTH (low debt)67 · sector 89
DIVIDEND (yield)31 · sector 42

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $438.12 $592.64 +35%
Fresenius SE FRE €45.57 €34.54 −24%
Dr. Sulaiman Al Habib Medical Services Group 4013 227.50 SAR 109.45 SAR −52%
IHH Healthcare Berhad, an investment holding company, 5225 8.00 MYR 4.87 MYR −39%
Tenet Healthcare Corporation THC $262.06 $399.58 +52%
DaVita Inc DVA $183.72 $255.97 +39%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹9,069 ₹2,908 −68%
Fresenius Medical Care AG FME €39.30 €71.28 +81%
Aier Eye Hospital Group 300015 ¥8.07 ¥10.86 +35%
Encompass Health Corporation EHC $122.76 $96.51 −21%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Xian International Medical Investment Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/000516

Frequently asked questions

Is Xian International Medical Investment Co Ltd (000516) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥3.42 versus a price of ¥4.32, about −21% upside (overvalued).
What is the fair value of 000516?
Our model-based fair value for Xian International Medical Investment Co Ltd is ¥3.42 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥4.32.
What is the quality score of 000516?
Xian International Medical Investment Co Ltd has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Xian International Medical Investment Co Ltd (000516)?
Our model-based price target is the fair value of ¥3.42 (as of Sep 24, 2026) from 11 valuation models. Cautious scenario ¥2.14, optimistic scenario ¥5.02. It is a calculation from audited fundamentals, not an analyst target.
What is the Xian International Medical Investment Co Ltd stock forecast for 2026?
Our models put fair value at ¥3.42, about −21% upside versus a price of ¥4.32 (overvalued). Cautious scenario ¥2.14, optimistic scenario ¥5.02. The calculation is refreshed regularly with new filings.
What is the revenue of Xian International Medical Investment Co Ltd (000516)?
Xian International Medical Investment Co Ltd reported trailing-twelve-month revenue of about 4.0B CNY (latest available figure, as of Sep 24, 2026).
Does Xian International Medical Investment Co Ltd pay a dividend?
Xian International Medical Investment Co Ltd currently shows a dividend yield of about 1.57% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Xian International Medical Investment Co Ltd (000516)?
For today's price to be fair in a discounted-cash-flow model, Xian International Medical Investment Co Ltd would have to grow free cash flow by +1.9 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +20.5 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 000516 use?
Our models discount Xian International Medical Investment Co Ltd at 10.4 %: a base by market capitalisation (small), damped by beta 0.16, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Xian International Medical Investment Co Ltd that is +1.9 % per year a year over ten years, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Xian International Medical Investment Co Ltd (000516) delivered so far?
Over the past 5 years revenue at Xian International Medical Investment Co Ltd grew +20.5 % a year. The price currently implies +1.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Xian International Medical Investment Co Ltd (000516) growing?
The median revenue growth in the sector is +2.5 % a year. That is the yardstick for the growth priced into Xian International Medical Investment Co Ltd (+1.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Xian International Medical Investment Co Ltd (000516)?
The free-cash-flow yield on the price is 10.48 %: that much free cash flow Xian International Medical Investment Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Xian International Medical Investment Co Ltd (000516)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Xian International Medical Investment Co Ltd it is ¥3.42 per share (as of Sep 24, 2026), against a price of ¥4.32. It is the blended result of 11 valuation models (cash flow, earnings, asset, dividend).
Is Xian International Medical Investment Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 000516 trades above its calculated fair value: price ¥4.32, fair value ¥3.42, a gap of about −21% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 000516?
No. The price is what the market pays today (¥4.32); the fair value is what the company's own numbers justify (¥3.42). For Xian International Medical Investment Co Ltd the two are ¥0.9000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Xian International Medical Investment Co Ltd worth?
The market values Xian International Medical Investment Co Ltd at about 9.7B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥4.32; our models calculate a fair value of ¥3.42 per share.
What do the bullish and bearish scenarios say about 000516?
Our models span a range for Xian International Medical Investment Co Ltd: cautious scenario ¥2.14, base ¥3.42, optimistic ¥5.02 per share (as of Sep 24, 2026, price ¥4.32). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Xian International Medical Investment Co Ltd (000516)?
Balance-sheet figures for Xian International Medical Investment Co Ltd (as of Sep 24, 2026): return on equity −11.5%, debt of 0.65 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is 000516 from its 52-week high?
Xian International Medical Investment Co Ltd trades at ¥4.32, about 30% below its 52-week high of ¥6.19 and 12% above the low of ¥3.86 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥3.42 is for.
Which stocks are comparable to Xian International Medical Investment Co Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Xian International Medical Investment Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price ¥4.32, calculated fair value ¥3.42 (−21%), Quality Score 54/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 000516 calculated?
We run Xian International Medical Investment Co Ltd through 11 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥3.42, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Xian International Medical Investment Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Xian International Medical Investment Co Ltd (000516)?
The closing price on Sep 22, 2026 was ¥4.32. Our model-based fair value is ¥3.42, about −21% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Xian International Medical Investment Co Ltd right now?
Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥2.14 to ¥5.02) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Xian International Medical Investment Co Ltd

How large is the market capitalisation of Xian International Medical Investment Co Ltd (000516)?
The market capitalisation of Xian International Medical Investment Co Ltd is 9.7B CNY (≈ $1.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Xian International Medical Investment Co Ltd (000516)?
The price-to-sales ratio of Xian International Medical Investment Co Ltd is 2.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Xian International Medical Investment Co Ltd (000516)?
Earnings per share at Xian International Medical Investment Co Ltd are ¥−0.1100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Xian International Medical Investment Co Ltd (000516)?
The dividend yield of Xian International Medical Investment Co Ltd is 1.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Xian International Medical Investment Co Ltd (000516)?
The net margin of Xian International Medical Investment Co Ltd is −7.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Xian International Medical Investment Co Ltd (000516)?
The return on equity (ROE) of Xian International Medical Investment Co Ltd is −11.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Xian International Medical Investment Co Ltd (000516)?
On an EBIT basis the return on assets of Xian International Medical Investment Co Ltd is −5.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Xian International Medical Investment Co Ltd (000516)?
The operating margin of Xian International Medical Investment Co Ltd is −4.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Xian International Medical Investment Co Ltd (000516)?
Revenue at Xian International Medical Investment Co Ltd is growing −2.8% versus a year earlier (3y avg +14.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Xian International Medical Investment Co Ltd (000516) carry?
The net debt of Xian International Medical Investment Co Ltd is 2.8B CNY (fiscal year 2025, ≈ 2.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Xian International Medical Investment Co Ltd in the live analysis

One click puts Xian International Medical Investment Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.